Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study)

Werner Klein, Arnd Buchwald, W. Stewart Hillis, E. Scott Monrad, Ginés Sanz, Alexander G G Turpie, Jan Van Der Meer, Eric Olaisson, Sven Undeland, Karin Ludwig

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The safety and efficacy of weight-adjusted, low-molecular-weight heparin (dalteparin) was compared with that of unfractionated heparin during 6 days of treatment in 1,482 patients with unstable angina or non-Q-wave myocardial infarction. Dalteparin, at a lower dose, was compared with placebo during the following 39 days. No significant outcome difference was found between the 2 treatment regimens in the unblinded phase (days 1-6). Between days 6-45 the rates of death, myocardial infarction, and recurrence of angina were comparable between the active treatment and placebo groups. The results suggest that twice-daily administration of subcutaneous dalteparin may be an effective and safe alternative to unfractionated heparin during the acute phase of unstable coronary artery disease. Prolonged treatment with dalteparin at a lower once daily dose did not confer any additional benefit over aspirin (75-165 mg) alone.

Original languageEnglish (US)
JournalAmerican Journal of Cardiology
Volume80
Issue number5 A
DOIs
StatePublished - Sep 4 1997
Externally publishedYes

Fingerprint

Dalteparin
Unstable Angina
Myocardial Infarction
Heparin
Placebos
Low Molecular Weight Heparin
Therapeutics
Aspirin
Coronary Artery Disease
Safety
Weights and Measures
Recurrence
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). / Klein, Werner; Buchwald, Arnd; Hillis, W. Stewart; Monrad, E. Scott; Sanz, Ginés; Turpie, Alexander G G; Van Der Meer, Jan; Olaisson, Eric; Undeland, Sven; Ludwig, Karin.

In: American Journal of Cardiology, Vol. 80, No. 5 A, 04.09.1997.

Research output: Contribution to journalArticle

Klein, W, Buchwald, A, Hillis, WS, Monrad, ES, Sanz, G, Turpie, AGG, Van Der Meer, J, Olaisson, E, Undeland, S & Ludwig, K 1997, 'Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study)', American Journal of Cardiology, vol. 80, no. 5 A. https://doi.org/10.1016/S0002-9149(97)00487-6
Klein, Werner ; Buchwald, Arnd ; Hillis, W. Stewart ; Monrad, E. Scott ; Sanz, Ginés ; Turpie, Alexander G G ; Van Der Meer, Jan ; Olaisson, Eric ; Undeland, Sven ; Ludwig, Karin. / Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). In: American Journal of Cardiology. 1997 ; Vol. 80, No. 5 A.
@article{8c30672eeea54dcba6eb6467a3196a14,
title = "Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study)",
abstract = "The safety and efficacy of weight-adjusted, low-molecular-weight heparin (dalteparin) was compared with that of unfractionated heparin during 6 days of treatment in 1,482 patients with unstable angina or non-Q-wave myocardial infarction. Dalteparin, at a lower dose, was compared with placebo during the following 39 days. No significant outcome difference was found between the 2 treatment regimens in the unblinded phase (days 1-6). Between days 6-45 the rates of death, myocardial infarction, and recurrence of angina were comparable between the active treatment and placebo groups. The results suggest that twice-daily administration of subcutaneous dalteparin may be an effective and safe alternative to unfractionated heparin during the acute phase of unstable coronary artery disease. Prolonged treatment with dalteparin at a lower once daily dose did not confer any additional benefit over aspirin (75-165 mg) alone.",
author = "Werner Klein and Arnd Buchwald and Hillis, {W. Stewart} and Monrad, {E. Scott} and Gin{\'e}s Sanz and Turpie, {Alexander G G} and {Van Der Meer}, Jan and Eric Olaisson and Sven Undeland and Karin Ludwig",
year = "1997",
month = "9",
day = "4",
doi = "10.1016/S0002-9149(97)00487-6",
language = "English (US)",
volume = "80",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5 A",

}

TY - JOUR

T1 - Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study)

AU - Klein, Werner

AU - Buchwald, Arnd

AU - Hillis, W. Stewart

AU - Monrad, E. Scott

AU - Sanz, Ginés

AU - Turpie, Alexander G G

AU - Van Der Meer, Jan

AU - Olaisson, Eric

AU - Undeland, Sven

AU - Ludwig, Karin

PY - 1997/9/4

Y1 - 1997/9/4

N2 - The safety and efficacy of weight-adjusted, low-molecular-weight heparin (dalteparin) was compared with that of unfractionated heparin during 6 days of treatment in 1,482 patients with unstable angina or non-Q-wave myocardial infarction. Dalteparin, at a lower dose, was compared with placebo during the following 39 days. No significant outcome difference was found between the 2 treatment regimens in the unblinded phase (days 1-6). Between days 6-45 the rates of death, myocardial infarction, and recurrence of angina were comparable between the active treatment and placebo groups. The results suggest that twice-daily administration of subcutaneous dalteparin may be an effective and safe alternative to unfractionated heparin during the acute phase of unstable coronary artery disease. Prolonged treatment with dalteparin at a lower once daily dose did not confer any additional benefit over aspirin (75-165 mg) alone.

AB - The safety and efficacy of weight-adjusted, low-molecular-weight heparin (dalteparin) was compared with that of unfractionated heparin during 6 days of treatment in 1,482 patients with unstable angina or non-Q-wave myocardial infarction. Dalteparin, at a lower dose, was compared with placebo during the following 39 days. No significant outcome difference was found between the 2 treatment regimens in the unblinded phase (days 1-6). Between days 6-45 the rates of death, myocardial infarction, and recurrence of angina were comparable between the active treatment and placebo groups. The results suggest that twice-daily administration of subcutaneous dalteparin may be an effective and safe alternative to unfractionated heparin during the acute phase of unstable coronary artery disease. Prolonged treatment with dalteparin at a lower once daily dose did not confer any additional benefit over aspirin (75-165 mg) alone.

UR - http://www.scopus.com/inward/record.url?scp=0030798740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030798740&partnerID=8YFLogxK

U2 - 10.1016/S0002-9149(97)00487-6

DO - 10.1016/S0002-9149(97)00487-6

M3 - Article

C2 - 9296467

AN - SCOPUS:0030798740

VL - 80

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5 A

ER -